A detailed history of Private Capital Group, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Private Capital Group, LLC holds 20 shares of HALO stock, worth $915. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20
Previous 20 -0.0%
Holding current value
$915
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 24, 2022

BUY
$31.82 - $40.75 $477 - $611
15 Added 300.0%
20 $1,000
Q3 2021

Oct 13, 2021

SELL
$38.47 - $46.42 $1,000 - $1,206
-26 Reduced 83.87%
5 $0
Q2 2021

Jul 26, 2021

BUY
$38.84 - $51.31 $1,204 - $1,590
31 New
31 $1,000
Q2 2020

Aug 13, 2020

SELL
$16.25 - $26.81 $585 - $965
-36 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$15.2 - $17.69 $547 - $636
36 New
36 $1,000
Q2 2019

Aug 15, 2019

SELL
$14.75 - $17.26 $531 - $621
-36 Closed
0 $0
Q4 2018

Jan 28, 2019

BUY
$13.33 - $18.66 $479 - $671
36 New
36 $1,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.37B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Private Capital Group, LLC Portfolio

Follow Private Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Capital Group, LLC with notifications on news.